-
Sotorasib is a first-in-class, orally bioavailable, and selective KRAS G12C covalent inhibitor, which inhibits tumor growth in mice. -
Amivantamab is an EGFR-MET bispecific monoclonal antibody for the treatment of non-small cell lung cancer. -
Adagrasib (MRTX849) is an orally available, and mutation-selective covalent inhibitor of KRAS G12C. Can be used for NSCLC research. -
A947 is a selective SMARCA2 (PROTAC). A947 also is a moderately selective SMARCA2 degrader. A947 can be used for the research of cancer. -
CYD-2-11 is a selective Bax agonist with antitumor activities in vitro and vivo and the inducing of cell apoptosis. -
Reversin 121 is a potent P-glycoprotein inhibitor that reverses P-glycoprotein-mediated multidrug resistance. -
JBJ-09-063 is a mutant-selective allosteric EGFR inhibitor. JBJ-09-063 can be used for EGFR-mutant lung cancer research. -
Serplulimab is a humanized monoclonal anti-PD-1 antibody and has the potential for the research of small cell lung cancer. -
BT5528 is a bicyclic peptide toxin conjugate, an EphA2 activator. BT5528 shows potent anti-tumor activity. -
G12Si-5, a potent, selective and reversible covalent inhibitor of the K-Ras G12S, can be used for the research of cancer.
Categories
Diseases
Others
Archives
- March 2023 (1)
- January 2023 (1)
- December 2022 (4)
- November 2022 (2)
- October 2022 (1)
- September 2022 (2)
- August 2022 (1)
- July 2022 (1)
- March 2022 (2)
- February 2022 (2)
- January 2022 (3)
- December 2021 (4)
- October 2021 (4)
- August 2021 (1)
- July 2021 (3)
- June 2021 (6)
- May 2021 (3)
- April 2021 (2)
- March 2021 (4)
- February 2021 (2)
- January 2021 (2)
- December 2020 (2)
- November 2020 (4)
- October 2020 (3)
- September 2020 (1)
- August 2020 (4)
- May 2020 (2)
- April 2020 (3)
- March 2020 (3)
- February 2020 (1)
- January 2020 (1)
- December 2019 (3)
- November 2019 (2)
- October 2019 (5)
- September 2019 (1)
- August 2019 (3)
- July 2019 (2)
- June 2019 (2)
- May 2019 (1)
- April 2019 (2)
